Document |
Document Title |
WO/2023/143427A1 |
The present application relates to the field of drug synthesis, in particular to a crystal form of ARV-110 and a preparation method therefor and a use thereof. The crystal form of the ARV-110 at least has one of the following improved ch...
|
WO/2023/143112A1 |
Disclosed are a salt form and a crystal form of an azabenzo eight-membered ring compound and an application thereof. Specifically disclosed are a crystal form A, crystal form B, crystal form C, and crystal form D of fumarate salt, hydroc...
|
WO/2023/141852A1 |
Disclosed are compounds represented by formula 1a or formula 1b, and respective optical isomers, prodrugs, or pharmaceutically acceptable salts, and pharmaceutical compositions thereof, and the use thereof in the preparation of CDK2 inhi...
|
WO/2023/144379A1 |
The present invention relates to ligands of Fibroblast Activation Protein (FAP) for the active delivery of various payloads (e.g. cytotoxic drugs, radionuclides, fluorophores, proteins and immunomodulators) at the site of disease. In par...
|
WO/2023/142231A1 |
A preparation method for C3-alkylated indole, in which elemental iodine is used as a catalyst, silane is used as a reducing agent and a carbonyl compound is used as an alkylation reagent, and the C3-alkylated indole is prepared under mil...
|
WO/2023/146991A1 |
Provided are compounds of Formula (I): (I), and pharmaceutically acceptable salts thereof, and pharmaceutical compositions, processes of preparing and methods of treating thereof; wherein Ring A, Ring B, X, R1, R2 and n are as defined he...
|
WO/2023/143370A1 |
The present invention relates to a compound represented by general formula (I), or stereoisomers, deuterated substances, solvates, prodrugs, metabolites, pharmaceutically acceptable salts or eutectic crystals thereof, an intermediate the...
|
WO/2023/143090A1 |
Provided is a crystalline form N1 of apalutamide hexafluoroisopropanol solvate and a preparation method therefor. The obtained crystalline form N1 exhibits good physicochemical stability, crystalline stability, and hygroscopicity. The pr...
|
WO/2023/143388A1 |
Provided are an amide compound as a potassium channel regulator, and the preparation therefor and the use thereof. The compound has a structure as represented by formula I, wherein the definition of each group and substituent is as descr...
|
WO/2023/143502A1 |
A precursor compound for forming a radionuclide complex, having the structure of formula I or formula II: wherein L is selected from -(CH2)m- and -CH2-PEG4-CH2-; L1 is -C(O)-L-NH-; BFC is a bifunctional chelating agent. A radiopharmaceut...
|
WO/2023/147418A1 |
Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or deuterated analog thereof, a pharmaceutical composition comprising a compound of the present invention, togeth...
|
WO/2023/142492A1 |
The present application relates to the field of organic light-emitting materials, and in particular to an organic compound, an electronic component, and an electronic device. The structure of the organic compound is as represented by for...
|
WO/2023/143321A1 |
A new crystal form of tavapadon (hereinafter referred to as "compound I"), a preparation method therefor, a pharmaceutical composition containing the crystal form, and the use of the crystal form in the preparation of a dopamine D1/D5 re...
|
WO/2023/144053A1 |
Compounds of the formula (I) Q1-Q2-Q3 in which Q1, Q2 and Q3 have the meanings indicated in Claim 1, degrade target proteins, and can be employed, inter alia, for the treatment of diseases such as cancer, multiple sclerosis, cardiovascul...
|
WO/2023/139379A1 |
This invention relates to novel compounds and pharmaceutical compositions comprising the novel compounds. More specifically, the invention relates to compounds useful as modulators of Rho-associated protein kinase (ROCK), for example ROC...
|
WO/2023/138647A1 |
The present disclosure relates to a crystalline form of a sulfur-containing isoindoline derivative. Specifically, the present disclosure relates to a crystalline form of a compound as represented by formula (I) and a preparation method t...
|
WO/2023/138583A1 |
Provided in the present invention are a heterocyclic compound, a pharmaceutical composition and the use thereof. Specifically disclosed are a heterocyclic compound as represented by formula (I-0), a pharmaceutically acceptable salt or st...
|
WO/2023/139085A1 |
The invention relates to a compound of formula (I) wherein A1, A2, A3, R1, R2, R2', R3, R4 and R5 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.
|
WO/2023/139084A1 |
The invention relates to a compound of formula (I) wherein A1, R1, R2, R3, R4 and R5 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.
|
WO/2023/139534A1 |
Provided herein are compounds of formula (I) and pharmaceutical compositions thereof useful for treating diseases or disorders mediated by the complement factor B. (I).
|
WO/2023/137966A1 |
The present invention provides a new crystal form of delafloxacin meglumine and a preparation method therefor. An X-ray powder diffraction pattern thereof has diffraction peaks at the following angles of 2θ: 7.323 ±0.2º, 8.079 ±0.2º...
|
WO/2023/138684A1 |
It relates generally to GLP-1 agonists and pharmaceutical compositions comprising the same, as well as methods for treating a GLP-1 associated disease, disorder, or condition.
|
WO/2023/138541A1 |
Disclosed are a picolinamide PARP inhibitor, and a preparation method therefor and the medical use thereof. Specifically, the present invention relates to a new compound as represented by general formula (1) and/or a pharmaceutically acc...
|
WO/2023/138674A1 |
The present invention relates to an N-hydroxyquinoline carboxamide derivative (I), and a preparation method therefor and the use thereof. The present invention further relates to a pharmaceutical composition containing the N-hydroxyquino...
|
WO/2023/141082A1 |
The present disclosure encompasses solid state forms of Tipifarnib, processes for preparation thereof, and pharmaceutical compositions thereof.
|
WO/2023/141635A2 |
Described herein, inter alia, are compositions of HER3 ligands and methods for treating diseases using the same.
|
WO/2023/139581A1 |
Compounds represented by Formula I: (I) wherein A, B, W, V, Z, Ra, Rb, n and m are as defined in the instant specification, or by Formula la, lb, III, IV or V, as defined in the instant specification, and uses thereof in modulating an ac...
|
WO/2023/139199A1 |
Compounds of Formula (I) or a pharmaceutically acceptable salt thereof are PROTAC compounds useful in the treatment of prostate cancer.
|
WO/2023/138412A1 |
The present disclosure relates to compounds of Formula (I) or pharmaceutically acceptable salts, solvate, stereoisomer, or isotopic variant thereof useful as CDK20 inhibitors, pharmaceutical compositions comprising the same, and use ther...
|
WO/2023/138657A1 |
A quinoline amine compound, a preparation method therefor, and the use thereof in medicine. Specifically, the present disclosure relates to a quinoline amine compound represented by general formula (I), a preparation method therefor, a p...
|
WO/2023/138599A1 |
An aromatic fused ring compound which acts as a sodium channel blocker, and a use thereof. The aromatic fused ring compound has inhibitory activity on sodium ion channel Nav1.8, and may be used as a drug for a wide range of pain treatment.
|
WO/2023/138607A1 |
Provided are novel bifunctional compounds formed by conjugating EGFR inhibitor moieties with E3 ligase Ligand moieties, which function to recruit targeted proteins to E3 ubiquitin ligase for degradation, and methods of preparation and us...
|
WO/2023/139462A1 |
Pharmaceutical compositions (A, G1-G8) capable of inhibiting the ATP-dependent proton pump (V-ATPase) and carbonic α-anhydrases (CA IV, IX and XII), having the general formulae: Formula A (PPI-CAI), G1, G2, G3, G4, G5, G6, G7 and G8 and...
|
WO/2023/141290A1 |
Described herein are PARP1 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of cancer.
|
WO/2023/139536A1 |
The present invention provides compounds of formula (I) as poly(ADP-ribose) polymerase 7 (PARP7) inhibitors, methods of preparing them, pharmaceutical compositions containing them and their use in methods of treatment, prevention and/or ...
|
WO/2023/138675A1 |
Provided are a quinoline derivative represented by formula (I) that can be used as a lactate dehydrogenase inhibitor, a pharmaceutical composition thereof, a preparation method therefor, and a use thereof.
|
WO/2023/134764A1 |
The present invention relates to a pyridine-containing polycyclic derivative, and a preparation method therefor and the use thereof. In particular, the present invention relates to a compound as represented by general formula (I), a prep...
|
WO/2023/134582A1 |
Provided are pyrimidine-2,4-diamine derivatives and the use thereof. The pyrimidine-2,4-diamine derivatives are specifically represented by formula (I). Also provided are a racemate, a tautomer, an enantiomer, a diastereomer, an isotopic...
|
WO/2023/134752A1 |
The present invention provides a diaryl compound as a tubulin/Src dual target inhibitor. The present invention also provides a diaryl compound represented by formula I, a tautomer, a stereoisomer, a solvate, a pharmaceutically acceptable...
|
WO/2023/137353A1 |
Described herein are 15-PGDH inhibitors and methods of utilizing 15-PGDH inhibitors in the treatment of diseases, disorders or conditions. Also described herein are pharmaceutical compositions containing such compounds.
|
WO/2023/137356A1 |
Described herein are 15-PGDH inhibitors and methods of utilizing 15-PGDH inhibitors in the treatment of diseases, disorders or conditions. Also described herein are pharmaceutical compositions containing such compounds.
|
WO/2023/135107A1 |
The present invention relates to a compound of general formula (I) inhibiting the transforming growth factor-β (TGF-β) type I receptor (ALK5), methods of preparing such compounds, pharmaceutical compositions containing them and therape...
|
WO/2023/133645A1 |
Radiolabeled compounds that target fibroblast activation protein (FAP). The compounds have 1-6 radiolabeling groups and 1-6 FAP-targeting groups, connected by 1-11 linkers. FAP-targeting groups have the structure of Formula (I). R1a and ...
|
WO/2023/134765A1 |
The present invention relates to five-membered-ring-containing derivatives, a preparation method therefor, and the uses thereof. In particular, the present invention relates to compounds represented by a general formula, a preparation me...
|
WO/2023/134686A1 |
The present invention relates to the field of drug synthesis, particularly, to a preparation method for a 1,3,5-triazine derivative, more particularly, to a preparation method for 4-(tert-butoxyamino)-6-(6-(trifluoromethyl)pyridin-2-yl)-...
|
WO/2023/137034A1 |
This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes...
|
WO/2023/134730A1 |
The present invention provides a pyrrolidine compound represented by formula (I) and a pharmaceutically acceptable salt thereof, and a use thereof as a coronavirus 3CL protease inhibitor in the prevention or treatment of related diseases...
|
WO/2023/134751A1 |
Disclosed in the present invention are a tubulin-Src dual-target inhibitor and the use thereof. The present invention provides a compound as shown in formula I, a tautomer, a stereoisomer, a solvate, a pharmaceutically acceptable salt or...
|
WO/2023/134266A1 |
A 2-piperidyl or 2-pyrazolyl substituted pyrimidine compound, which is a compound represented by formula (I) or a pharmaceutically acceptable salt, an isotopic variant, a tautomer, a stereoisomer, a prodrug, a polymorph, a hydrate or a s...
|
WO/2023/130878A1 |
Provided are an (S)-2-((6-((4-cyano-2-fluorobenzyl)oxy)-3',6'-dihydro-[2,4'-
bipyridyl-1'(2'H)-yl)methyl)-1(oxetan-2-ylmethyl)-1H-thieno[
2,3-d]imidazole-5-carboxylic acid compound, a salt or a salt crystal of the compound, a preparation...
|